Item Type | Name |
Academic Article
|
The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.
|
Academic Article
|
Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy.
|
Concept
|
Melanoma
|
Concept
|
Melanoma, Experimental
|
Academic Article
|
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).
|
Academic Article
|
Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2.
|
Academic Article
|
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.
|
Academic Article
|
Special issue on melanoma.
|
Academic Article
|
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.
|
Academic Article
|
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.
|
Academic Article
|
Tissue resources for clinical use and marker studies in melanoma.
|
Academic Article
|
Emerging insights into resistance to BRAF inhibitors in melanoma.
|
Academic Article
|
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
|
Academic Article
|
Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
|
Academic Article
|
Prognostic factors for survival in melanoma patients with brain metastases.
|
Academic Article
|
Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function.
|
Academic Article
|
Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma.
|
Academic Article
|
In vitro studies of dasatinib, its targets and predictors of sensitivity.
|
Academic Article
|
Exome sequencing identifies GRIN2A as frequently mutated in melanoma.
|
Academic Article
|
Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
|
Academic Article
|
BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.
|
Academic Article
|
Overcoming resistance to MAPK pathway inhibitors.
|
Academic Article
|
Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.
|
Academic Article
|
Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin.
|
Academic Article
|
A novel AKT3 mutation in melanoma tumours and cell lines.
|
Academic Article
|
Phosphorylated 4E-BP1 is associated with poor survival in melanoma.
|
Academic Article
|
Phosphatidylinositol-3-kinase as a therapeutic target in melanoma.
|
Academic Article
|
Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.
|
Academic Article
|
Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid.
|
Academic Article
|
Targeted therapy for melanoma: a primer.
|
Academic Article
|
Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma.
|
Academic Article
|
Association of activated c-Met with NRAS-mutated human melanomas.
|
Academic Article
|
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma.
|
Academic Article
|
Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases.
|
Academic Article
|
A landscape of driver mutations in melanoma.
|
Academic Article
|
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.
|
Academic Article
|
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
|
Academic Article
|
Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2.
|
Academic Article
|
Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.
|
Academic Article
|
Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.
|
Academic Article
|
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
|
Academic Article
|
The role of the PI3K-AKT pathway in melanoma.
|
Academic Article
|
Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells.
|
Academic Article
|
A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.
|
Academic Article
|
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
|
Academic Article
|
Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma.
|
Academic Article
|
NRAS mutation status is an independent prognostic factor in metastatic melanoma.
|
Academic Article
|
New strategies in melanoma: molecular testing in advanced disease.
|
Academic Article
|
Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-a in patients with metastatic melanoma.
|
Academic Article
|
Finding the right balance of BRAF inhibition in melanoma.
|
Academic Article
|
Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target.
|
Academic Article
|
Targeted therapy resistance mechanisms and therapeutic implications in melanoma.
|
Academic Article
|
A highly recurrent RPS27 5'UTR mutation in melanoma.
|
Academic Article
|
The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.
|
Academic Article
|
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.
|
Academic Article
|
Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations.
|
Academic Article
|
Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1a and oxidative phosphorylation in melanoma.
|
Academic Article
|
Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations.
|
Academic Article
|
BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma.
|
Academic Article
|
Role and complexity of next-generation sequencing in melanoma.
|
Academic Article
|
Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma.
|
Academic Article
|
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
|
Academic Article
|
BRAF in early stage melanoma: rationale for testing and treatment?
|
Academic Article
|
ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.
|
Academic Article
|
Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report.
|
Academic Article
|
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
|
Academic Article
|
Melanoma central nervous system metastases
|
Academic Article
|
Clinicopathological features and clinical outcomes associated with TP53 and BRAFN on- V 600 mutations in cutaneous melanoma patients
|
Academic Article
|
Molecular biology of cutaneous melanoma
|
Academic Article
|
Molecular biology of cutaneous melanoma
|
Academic Article
|
Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma
|
Academic Article
|
SBI-0640756 attenuates the growth of clinically unresponsive melanomas by disrupting the eIF4F translation initiation complex
|
Academic Article
|
Role and complexity of next-generation sequencing in melanoma
|
Academic Article
|
A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma
|
Academic Article
|
Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma
|
Academic Article
|
An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma
|
Academic Article
|
PDK1 and SGK3 contribute to the growth of BRAF-mutant melanomas and are potential therapeutic targets
|
Academic Article
|
AKT1 Activation Promotes Development of Melanoma Metastases
|
Academic Article
|
Molecular approaches to tumor inhibition in melanoma
|
Academic Article
|
Targeted therapy for melanoma
|
Academic Article
|
Genotyping of cutaneous melanoma
|
Academic Article
|
Inflammatory marker testing identifies CD74 expression in melanoma tumor cells, and its expression associates with favorable survival for stage III melanoma
|
Academic Article
|
RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma
|
Academic Article
|
Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma
|
Academic Article
|
BRAFV600E co-opts a conserved MHC class I internalization pathway to diminish antigen presentation and CD8+ T-cell recognition of melanoma
|
Academic Article
|
The multi-faceted roles of the PI3K-AKT pathway in melanoma
|
Academic Article
|
RAC1 P29S regulates PD-L1 expression in melanoma
|
Academic Article
|
Integrated molecular and clinical analysis of AKT activation in metastatic melanoma
|
Academic Article
|
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
|
Academic Article
|
Targeting Notch enhances the efficacy of ERK inhibitors in BRAFV600E melanoma
|
Academic Article
|
Future perspectives in melanoma research
|
Academic Article
|
Future perspectives in melanoma research
|
Academic Article
|
MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRASĂ‚Â Melanoma
|
Academic Article
|
Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes.
|
Academic Article
|
The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression.
|
Academic Article
|
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.
|
Academic Article
|
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
|
Academic Article
|
Genotyping of cutaneous melanoma.
|
Academic Article
|
Converting biology into clinical benefit: lessons learned from BRAF inhibitors.
|
Academic Article
|
Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma.
|
Academic Article
|
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
|
Academic Article
|
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.
|
Academic Article
|
Molecular approaches to tumor inhibition in melanoma.
|
Academic Article
|
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
|
Academic Article
|
Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases.
|
Academic Article
|
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.
|
Academic Article
|
Melanoma Brain Metastases: Current Areas of Investigation and Future Directions.
|
Academic Article
|
A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
|
Academic Article
|
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
|
Academic Article
|
Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.
|
Academic Article
|
Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications.
|
Academic Article
|
Melanoma in 2017: Moving treatments earlier to move further forwards.
|
Academic Article
|
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.
|
Academic Article
|
Primary medical therapy for BRAFV600E-mutant melanoma brain metastases-is this good enough? - Authors' reply.
|
Academic Article
|
Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.
|
Academic Article
|
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
|
Academic Article
|
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
|
Academic Article
|
A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling.
|
Academic Article
|
Phase I/II Study of Hepatic Arterial Infusion of Nab-paclitaxel in Patients With Metastatic Melanoma to the Liver.
|
Academic Article
|
Body-mass index and metastatic melanoma outcomes - Authors' reply.
|
Academic Article
|
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
|
Academic Article
|
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
|
Academic Article
|
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
|
Academic Article
|
Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).
|
Academic Article
|
Reply to A. Shinde et al.
|
Academic Article
|
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.
|
Academic Article
|
Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas.
|
Academic Article
|
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.
|
Academic Article
|
Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3K? Inhibition in PTEN Loss Melanoma.
|
Academic Article
|
Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features.
|
Academic Article
|
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
|
Academic Article
|
Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions.
|
Academic Article
|
B cells and tertiary lymphoid structures promote immunotherapy response.
|
Academic Article
|
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma.
|
Academic Article
|
Circulating Tumor Cells and Early Relapse in Node-positive Melanoma.
|
Academic Article
|
Is It Safe to Stop Anti-PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response?
|
Academic Article
|
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma.
|
Academic Article
|
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype.
|
Academic Article
|
Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report.
|
Academic Article
|
Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker.
|
Academic Article
|
Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases.
|
Academic Article
|
iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation.
|
Academic Article
|
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.
|
Academic Article
|
The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
|
Academic Article
|
Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era.
|
Academic Article
|
Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
|
Academic Article
|
Re-thinking therapeutic development for CNS metastatic disease.
|
Academic Article
|
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.
|
Academic Article
|
Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes.
|
Academic Article
|
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma.
|
Academic Article
|
Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.
|
Academic Article
|
Targeted therapy strategies for melanoma brain metastasis.
|
Academic Article
|
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.
|
Academic Article
|
Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma.
|
Academic Article
|
Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020.
|
Academic Article
|
Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition.
|
Academic Article
|
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
|
Academic Article
|
Neoadjuvant relatlimab and nivolumab in resectable melanoma.
|
Academic Article
|
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma.
|
Academic Article
|
Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma.
|
Academic Article
|
Changes in outcomes and factors associated with survival in melanoma patients with brain metastases.
|
Academic Article
|
Multiplatform Analysis of Intratumoral PTEN Heterogeneity in Melanoma.
|
Academic Article
|
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma.
|
Academic Article
|
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
|
Academic Article
|
Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma.
|